Last reviewed · How we verify
NCT04364724
CTFEA Myeloma Study
trial testing CT-based finite element analysis in Myeloma Multiple in 200 participants. Status unknown.
31 March 2023
Quick facts
| Lead sponsor | Tel-Aviv Sourasky Medical Center |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 June 2020 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2024 |
Drugs / interventions tested
- CT-based finite element analysis
Conditions studied
- Myeloma Multiple — all drugs for Myeloma Multiple →
- Metastatic Bone Tumor — all drugs for Metastatic Bone Tumor →
Sponsor
Tel-Aviv Sourasky Medical Center
Who can join
Adults 18 to 95, any sex, with Myeloma Multiple or Metastatic Bone Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with Multiple Myeloma are monitored for disease progression and for response to treatment by the treating hematologist or oncologist. Laboratory tests are usually utilized for these purposes. The role of imaging is confined to follow-up the progression of visible bone lesions. We suggest that microscopic bone lesions impair bone structure well before they grow enough to be visible on a CT scan. This impairment of bone strength can probably be captured by application of CT-based finite element analysis to the CT scans that were performed for monitoring of progression of the disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04364724
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myeloma Multiple
Currently open trials in the same condition.
- NCT07236021 — e-Motion : Promoting Emotion Regulation in Chronic Cancer · NA · recruiting
- NCT06245629 — Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma · recruiting
- NCT06911710 — The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors · Phase 1, PHASE2 · recruiting
- NCT05889221 — Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of · NA · active not recruiting
- NCT05651932 — A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma · Phase 1 · recruiting
Other Tel-Aviv Sourasky Medical Center trials
Trials by the same sponsor.
- NCT07380737 — Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot · NA · recruiting
- NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
- NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
- NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
- NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04364724 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
- Last refreshed: 28 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04364724.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing